Matches in SemOpenAlex for { <https://semopenalex.org/work/W3044546836> ?p ?o ?g. }
- W3044546836 endingPage "557" @default.
- W3044546836 startingPage "543" @default.
- W3044546836 abstract "Abstract Ovarian cancer (OC) is associated with poor survival because there are a limited number of effective therapies. Two processes key to OC progression, angiogenesis and immune evasion, act synergistically to promote tumor progression. Tumor-associated angiogenesis promotes immune evasion, and tumor-related immune responses in the peritoneal cavity and tumor microenvironment (TME) affect neovascular formation. Therefore, suppressing the angiogenic pathways could facilitate the arrival of immune effector cells and reduce the presence of myeloid cells involved in immune suppression. To date, clinical studies have shown significant benefits with antiangiogenic therapy as first-line therapy in OC, as well as in recurrent disease, and the vascular endothelial growth factor (VEGF) inhibitor bevacizumab is now an established therapy. Clinical data with immunomodulators in OC are more limited, but suggest that they could benefit some patients with recurrent disease. The preliminary results of two phase III trials have shown that the addition of immunomodulators to chemotherapy does not improve progression-free survival. For this reason, it could be interesting to look for synergistic effects between immunomodulators and other active drugs in OC. Since bevacizumab is approved for use in OC, and is tolerable when used in combination with immunotherapy in other indications, a number of clinical studies are underway to investigate the use of bevacizumab in combination with immunotherapeutic agents in OC. This strategy seeks to normalize the TME via the anti-VEGF actions of bevacizumab, while simultaneously stimulating the immune response via the immunotherapy. Results of these studies are awaited with interest." @default.
- W3044546836 created "2020-07-29" @default.
- W3044546836 creator A5010572721 @default.
- W3044546836 creator A5019869973 @default.
- W3044546836 creator A5049908989 @default.
- W3044546836 creator A5060081149 @default.
- W3044546836 creator A5081736939 @default.
- W3044546836 date "2020-07-20" @default.
- W3044546836 modified "2023-10-11" @default.
- W3044546836 title "Are antiangiogenics a good ‘partner’ for immunotherapy in ovarian cancer?" @default.
- W3044546836 cites W1518184777 @default.
- W3044546836 cites W1793338775 @default.
- W3044546836 cites W1985007222 @default.
- W3044546836 cites W1985804036 @default.
- W3044546836 cites W1987370132 @default.
- W3044546836 cites W2061123122 @default.
- W3044546836 cites W2067969350 @default.
- W3044546836 cites W2074196937 @default.
- W3044546836 cites W2076866768 @default.
- W3044546836 cites W2077255241 @default.
- W3044546836 cites W2083570617 @default.
- W3044546836 cites W2102195694 @default.
- W3044546836 cites W2102306754 @default.
- W3044546836 cites W2102979753 @default.
- W3044546836 cites W2106102605 @default.
- W3044546836 cites W2110578043 @default.
- W3044546836 cites W2113122060 @default.
- W3044546836 cites W2117115065 @default.
- W3044546836 cites W2121820529 @default.
- W3044546836 cites W2123113463 @default.
- W3044546836 cites W2128565827 @default.
- W3044546836 cites W2130522035 @default.
- W3044546836 cites W2131783235 @default.
- W3044546836 cites W2133537644 @default.
- W3044546836 cites W2135947389 @default.
- W3044546836 cites W2136313650 @default.
- W3044546836 cites W2137074525 @default.
- W3044546836 cites W2147622445 @default.
- W3044546836 cites W2148682310 @default.
- W3044546836 cites W2151509048 @default.
- W3044546836 cites W2151842614 @default.
- W3044546836 cites W2170928115 @default.
- W3044546836 cites W2171658624 @default.
- W3044546836 cites W2178370458 @default.
- W3044546836 cites W2186690436 @default.
- W3044546836 cites W2200887263 @default.
- W3044546836 cites W2251635988 @default.
- W3044546836 cites W2277189199 @default.
- W3044546836 cites W2292067704 @default.
- W3044546836 cites W2293618284 @default.
- W3044546836 cites W2318567174 @default.
- W3044546836 cites W2344322811 @default.
- W3044546836 cites W2344718331 @default.
- W3044546836 cites W2346727850 @default.
- W3044546836 cites W2417674265 @default.
- W3044546836 cites W2425731878 @default.
- W3044546836 cites W2473347405 @default.
- W3044546836 cites W2509217584 @default.
- W3044546836 cites W2518249527 @default.
- W3044546836 cites W2523680188 @default.
- W3044546836 cites W2560029343 @default.
- W3044546836 cites W2562844176 @default.
- W3044546836 cites W2578528809 @default.
- W3044546836 cites W2587333476 @default.
- W3044546836 cites W2589658059 @default.
- W3044546836 cites W2605004457 @default.
- W3044546836 cites W2605456582 @default.
- W3044546836 cites W2605792367 @default.
- W3044546836 cites W2607357764 @default.
- W3044546836 cites W2610368132 @default.
- W3044546836 cites W2618493603 @default.
- W3044546836 cites W2620731633 @default.
- W3044546836 cites W2623028642 @default.
- W3044546836 cites W2637198528 @default.
- W3044546836 cites W2725375820 @default.
- W3044546836 cites W2747774814 @default.
- W3044546836 cites W2748037493 @default.
- W3044546836 cites W2749849377 @default.
- W3044546836 cites W2751378276 @default.
- W3044546836 cites W2753911561 @default.
- W3044546836 cites W2765953690 @default.
- W3044546836 cites W2776825114 @default.
- W3044546836 cites W2779221466 @default.
- W3044546836 cites W2791328450 @default.
- W3044546836 cites W2792067978 @default.
- W3044546836 cites W2794419219 @default.
- W3044546836 cites W2803642760 @default.
- W3044546836 cites W2804661897 @default.
- W3044546836 cites W2805187906 @default.
- W3044546836 cites W2805354595 @default.
- W3044546836 cites W2805926640 @default.
- W3044546836 cites W2811145582 @default.
- W3044546836 cites W2811158315 @default.
- W3044546836 cites W2884366738 @default.
- W3044546836 cites W2890261294 @default.
- W3044546836 cites W2891245632 @default.
- W3044546836 cites W2895357007 @default.
- W3044546836 cites W2895870246 @default.